Memantine as an Additive Therapy in Patients With Traumatic Brain Injury

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

March 25, 2025

Primary Completion Date

August 30, 2025

Study Completion Date

November 30, 2025

Conditions
Mild Traumatic Brain InjuryModerate Traumatic Brain Injury (TBI)
Interventions
DRUG

Memantine

Memantine will be given either orally or through a nasogastric tube for 7 days, starting on the first day of admission to the hospital and then continued for 3 weeks. The memantine dose in the first 7 days is 30 mg twice daily, while during the remaining 3 weeks the dose is 10 mg twice daily

DRUG

Mannitol

Mild to moderate TBI patients will receive mannitol in case of brain edema to reduce brain swelling and analgesic for headache such as; acetaminophen.

Trial Locations (1)

35516

Mansoura University, Al Mansurah

All Listed Sponsors
lead

Mansoura University

OTHER

NCT06914310 - Memantine as an Additive Therapy in Patients With Traumatic Brain Injury | Biotech Hunter | Biotech Hunter